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ABSTRACT 
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease resulting 
from pathologically low levels of survival motor neuron (SMN) protein. The majority of mRNA 
from the SMN2 allele undergoes alternative splicing and excludes critical codons, causing an 
SMN protein deficiency. While there is currently no FDA-approved treatment for SMA, early 
therapeutic efforts have focused on testing repurposed drugs such as phenylbutyrate (2), valproic 
acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical 
effectiveness. More recently, clinical trials have focused on novel small-molecule compounds 
identified from high-throughput screening and medicinal chemistry optimization such as 
olesoxime (11), CK-2127107, RG7800, LMI070, and RG3039 (17). In this paper, we review 
both repurposed drugs and small-molecule compounds discovered following medicinal 
chemistry optimization for the potential treatment of SMA.    
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1. INTRODUCTION 
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder 
characterized by progressive muscle wasting and eventual loss of muscle function due to severe 
motor neuron dysfunction.1-4 As one of the leading heritable causes of infant mortality 
worldwide, SMA affects between 1 in 6,000 to 1 in 11,000 live births and has a carrier frequency 
of approximately 1 in 40 to 50 people.5-8 
The first cases of SMA were first published in the 1890s by Guido Werdnig and Johan 
Hoffman, two physicians whose autopsy studies revealed the key pathological feature of the 
disease:  severe loss of α-motor neurons (MNs) from the anterior horn of the spinal cord.9 A 
breakthrough study in 1995 mapped the SMA genes to chromosome 5q13, in which two nearly 
identical genes encode for the same SMN protein.10 Initially named telomeric and centromeric 
SMN, these genes are now more commonly referred to as SMN1 and SMN2, respectively.11 
These two genes are nearly identical and encode the same 294 residue, 38-kDa SMN protein.10,11 
Researchers later determined that SMN is ubiquitously expressed at high levels during 
embryonic and prenatal development before rapidly decreasing after birth.12  
SMN1 and SMN2 mRNAs are transcribed at similar levels in all cells, but approximately 
85% of SMN2 transcripts result in abnormal SMN protein due to a single nucleotide difference 
from C to T in the 6th nucleotide of exon 7 (encoding residue 840) of the SMN2 gene.13,14 The 
resulting ∆7 SMN2 mRNA is truncated, lacking the codons for 16 amino acids within exon 7 as 
well as the translational termination codon.15,16 The translated ∆7 protein is unstable and quickly 
degrades in cells.17-19 The majority of SMA patients lack both copies of the SMN1 gene 
altogether, and instead have two or more copies of the SMN2 gene.20 In such SMN1 null patients, 
SMN2 expression is the sole source of SMN protein. Accordingly, the SMN2 gene is unable to 
fully compensate for the loss of SMN1 due to its ∆7 mutation and decreased production of 
normal, full-length SMN protein.5 About 5% of SMA patients have mutations in the SMN1 gene 
that render it dysfunctional. 
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Figure 1. SMA is caused by a loss of SMN1. The two SMA genes, SMN1 and SMN2, are found 
on chromosome 5q11-13 and encode for SMN protein. In most patients with SMA, complete 
lack of an SMN1 gene results in all SMN protein being derived from SMN2 expression. Although 
all patients retain one or more copies of the SMN2 gene, it is unable to fully compensate for loss 
of SMN1. Only about 15% of SMN2 transcripts encode for normal, full-length SMN protein.5  
 
There are four types of SMA, which are classified by age of onset, age of death, achievements in 
motor development, and number of SMN2 copies.21 Type I (also known as Werdnig-Hoffman 
disease) patients demonstrate the most severe SMA symptoms and possess only 2 to 3 copies of 
SMN2. Within 6 months of birth, these patients are unable to sit unsupported due to their lack of 
muscle function.22,23 Type II SMA (also referred to as Dubowitz syndrome) patients possess 3 to 
4 copies of SMN2 and, notably, are able to sit unsupported.24 In general, Types III and IV are 
milder forms of SMA with much later onsets. Type III SMA, referred to as juvenile SMA or 
Kugelberg-Welander disease, typically manifests after 18 months in patients with 4 copies of 
SMN2. Type IV patients possess 4 to 8 copies of SMN2 and often demonstrate muscular 
dystrophy symptoms after adulthood.21,23,24 Plainly, there is an inverse relationship between the 
number of SMN2 copies and the phenotypic severity of this illness.25,26 A variety of SMA mouse 
models containing the transgenic human SMN2 gene were developed to reflect the range of 
disease severity observed in humans and have been used to evaluate compounds that increase 
transcription of SMN2, the inclusion of exon 7 in the SMN2 mRNA transcript, and levels of the 
SMN protein.27 The Δ7 SMA and the “Taiwanese” of “Li” models are the most commonly used 
severe mouse models of SMA in preclinical studies.28  Outcome measures in the severe models 
include survival (~10-14 days), motor function, neuromuscular junction (NMJ) number and 
morphology. Less severe mouse models include the 2B/- and Smn1C/C, which have mutated the 
single mouse Smn allele so that its exon 7 is skipped, as well as the SMNRT (SMN read through) 
and “Burgheron” models with longer survival times (~30-35 days).29-31 
Currently, there are seven clinical and 11 preclinical agents for SMA treatment, ranging 
from repurposed drugs, gene therapy, antisense oligonucleotides, and novel small molecules. 
Gene therapy is an experimental technique that inserts genes into cells via a viral vector. Genes 
can be delivered systemically by injection of the vectors intravenously or directly into the 
cerebral spinal fluid (CSF) to infect neurons. AveXis, the first company to test gene therapy in 
SMA clinical trials, has developed a proprietary intravenous treatment using self-complementary 
adeno-associated virus (scAAV-9) vectors that carry a codon-optimized SMN1 sequence and a 
chimeric intron that reintroduces SMN1 into MNs resulting in SMN protein overexpression.32 
The effectiveness of the scAAV-9 vector is attributed to its ability to cross the blood-brain 
barrier (BBB) and to infect neurons by retrograde trafficking from the axon. This modality is in 
Phase II clinical trials. Another experimental method, antisense oligonucleotide therapy, aims to 
deliver a synthetic strand of nucleic acids (DNA, RNA, or a chemically modified analogue) that 
binds a specific regulatory site on pre-mRNA, thereby modifying exon recognition. Ionis 
(formerly known as Isis) Pharmaceuticals and Biogen have collaborated to develop a chemically 
modified antisense ribonucleotide, IONIS-SMNRx, that binds to a splice silencer element in 
intron 7 of SMN2 and results in its inactivation and the inclusion of exon 7.33 Although these two 
treatment options demonstrate the innovative and new strategies being developed over the past 
few years, from here on, we will focus only on the biology and medicinal chemistry strategies 
associated with producing small molecule treatments for SMA. We review repurposed drugs as 
well as five clinical and six preclinical novel small molecules candidate therapies. 
2. REPURPOSED DRUGS 
Finding new uses for existing FDA-approved drugs offers several advantages, including 
shorter development and approval times, reduced costs, and higher success rates relative to the 
standard practice of developing new compounds. New drug development can take up to 16 
years34 and incurs significant costs during the drug discovery and preclinical stages.35 Drug 
repurposing avoids a number of these expensive processes and takes between three and 12 years 
for drug approval. Further, the success rates of repurposed drugs are drastically improved; while 
10% of new molecular entities from Phase II and 50% from Phase III clinical trials make it to 
market, the rates for repurposed compounds are 25% and 65%, respectively.36 With no strong 
clinical prospects in the SMA drug therapy pipeline, the cost-effective and potentially time-
saving testing of repurposed drugs was an attractive source of therapeutic drug discovery.  
SMA was granted orphan drug designation by the FDA, which assigns orphan status to 
drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of (i) 
rare diseases and/or disorders affecting fewer than 200,000 people in the U.S. or (ii) diseases 
and/or disorders affecting more than 200,000 persons, but that are not expected to recover the 
costs of developing and marketing a treatment drug.37  
FDA-approved drugs that enhance SMN2 promoter activity, modulate SMN2 splicing, 
and stabilize SMN2 mRNA or SMN protein, have been explored as potential means of treating 
SMA (Table 1). Though repurposed drugs examined for the treatment of SMA have resulted in 
promising early data, including increased levels of SMN protein, none has successfully made it 
through Phase III clinical trials. 
2.1 HISTONE DEACETYLASE INHIBITORS 
One group of drugs found to increase SMN2 promoter activity is histone deacetylase 
(HDAC) inhibitors. A basic epigenetic mechanism for regulating gene expression is through 
acetylation and deacetylation of selected lysines within the histones of chromatin. HDAC 
inhibitors are enzymes that deacetylate chromatin histones and create a tightly coiled, 
transcriptionally-repressed region of chromatin, and therefore inhibitors of these enzymes 
activate gene expression. One potential advantage of HDAC inhibitors is the ability to reverse 
abnormal cell transcription early on, rather than treating downstream translational 
endophenotypes. It was proposed that HDAC inhibition could induce transcription of SMN2 and, 
as a result, could increase the amount of total SMN2 transcripts, which would lead to more 
functional SMN protein.38 To date, several FDA-approved HDAC inhibitors have been 
investigated for the treatment of SMA. The first HDAC inhibitor to result in increased SMN2 
transcription was sodium butyrate (1).39 Subsequently, phenylbutyrate (2), valproic acid (3), 
suberoylanilide hydroxamic acid (4), and trichostatin A (5) all were shown to increase SMN2 
expression in patient-derived cell lines and animal models.40-44 Importantly, HDAC inhibition is 
not specific to SMN2, and the expression of multiple genes potentially would be altered, leading 
to side effects. The results of these approaches are discussed below. 
 
2.1.1 Sodium Butyrate 
The HDAC inhibitor 1 is a salt of butyric acid with antineoplastic activity.39 Chang et al. 
were the first to show that the SMN2 gene could be activated by 1.39 To generate lines of 
immortalized lymphoid cells, the researchers transformed lymphocytes obtained from SMA 
patients with Epstein-Barr virus. After exposing the lymphocytes to candidate drugs, they 
performed quantitative reverse transcriptase PCR (qRT-PCR) to determine which drugs resulted 
in increased production of full-length SMN2 mRNA. Compound 1 increased both SMN2 
transcription and the inclusion of exon 7 in SMN2 transcripts, thereby increasing the production 
of full-length SMN2 mRNA. A corresponding increase in SMN protein also was seen. Further, 
there was a 25% extension in the mean survival of Taiwanese SMA mice. The primary 
disadvantage of 1 is its very short half-life in human serum (T1/2 = 6 min), making it unsuitable 
for therapy.  
2.1.2 Sodium Phenylbutyrate 
In a subsequent study, 2, an analog of sodium butyrate, was found to increase full-length 
SMN2 mRNA and SMN protein in SMA patient-derived fibroblasts.40 Compound 2 is FDA-
approved for urea cycle disorder and has been tested for therapeutic benefit in amyotrophic 
lateral sclerosis (ALS), cystic fibrosis, and several cancers. Compound 2 is more stable, with a 
0.8-1 h half-life in human.45 There is evidence suggesting that 2 crosses the BBB; 2 was able to 
lower long-chain fatty acid levels in the brain of mice with x-linked adrenoleukodystrophy46 and, 
after IV administration, led to a CSF:plasma ratio of 1:2 in primates.47  
An uncontrolled, open-label pilot study investigated the use of 2 in Type II SMA patients 
and resulted in a 2-fold increase in SMN mRNA and improved Hammersmith Motor Function 
Scale scores.48 Two additional phase II/III clinical trials were terminated due to slow enrollment 
and poor compliance. STOPSMA, an open-label trial for 2, was conducted to evaluate the 
compound in pre-symptomatic infants with Types I and II SMA.49 Although the study was 
completed in 2013, outcomes have not been reported.   
 
2.1.3 Valproic Acid 
 Compound 3, an HDAC inhibitor of the aliphatic class, is a carboxylic acid with a pKa of 
4.8 that likely is fully ionized at physiological pH.50 However, 3 can cross the BBB via active 
transport by medium-chain fatty acid transporters. Compound 3 is used clinically for a number of 
central nervous system (CNS) diseases, including epilepsy and bipolar disorder, and to prevent 
migraine headaches.50 
Compound 3 treatment of SMA patient-derived primary fibroblasts resulted in a 2- to 4-
fold increase in SMN protein. This increase coincided with an increase in both total SMN2 
transcripts and full-length exon 7-included SMN2 transcripts.41,51 Further analyses revealed 
increased expression of several splicing factors, each of which had been shown previously to 
increase SMN2 exon 7 inclusion. A more recent study testing the efficacy of 3 in vitro confirmed 
an increase in total SMN2 mRNA, but reported no change in exon 7 inclusion levels.52 An in vivo 
test of 3 efficacy in homozygous 5058 SMA mice resulted in a 100% increase in median 
survival, a slight increase in SMN protein in the spinal cord, and improvements in muscle and 
neuron pathology.53 However, the authors noted decreases in growth cone size, axon length, 
motor neuron survival, and increased excitability in axon terminals, which suggested that 3 
might be detrimental to motor neuron survival and function.  
Five clinical trials using 3 in SMA have been conducted, but none has reported any 
clinical benefit. A randomized, prospective, placebo-controlled clinical trial designed to test the 
efficacy and safety of the combined administration of 3 with L-carnitine in ambulatory adults 
with Type III SMA was performed, but it demonstrated that 3 was not effective in improving 
strength or function in this population.54 
 
2.1.4 Suberoylanilide Hydroxamic Acid 
Compound 4, known as Vorinostat, is a potent, hydroxamic acid class HDAC inhibitor 
that inhibits class I and II HDAC inhibitors at submicromolar concentrations.42 Compound 4 is 
FDA-approved for the treatment of cutaneous T-cell lymphoma. In vitro experiments showed 
that 4 increased both SMN protein and mRNA in rat hippocampal neurons, motor neuron 
cultures, and primary SMA patient fibroblasts.42 As with other HDAC inhibitors, these increases 
coincided with an increase in exon 7 inclusion in SMN2 transcripts. Compound 4 efficacy also 
was examined in an in vivo study using 5024- and 5058-SMA mouse strains.43 Treatment with 4 
increased the lifespan of the SMA mice by 30%, significantly improved motor function abilities, 
reduced degeneration of motor neurons within the spinal cord, and increased the size of 
neuromuscular junctions and muscle fibers compared with vehicle-treated SMA mice. SMN 
RNA and protein levels were elevated significantly in various tissues, including spinal cord and 
muscle.43 Compound 4 demonstrated positive in vivo effects despite very poor brain access (e.g., 
brain to plasma ratios between 0.04 and 0.01). Its poor brain penetration likely is due to the fact 
that 4 is a substrate for the P-glycoprotein (P-gp) and Bcrp1 efflux transporters at the BBB. 
These transporters are expressed at the blood and spinal cord brain barriers and restrict a number 
of drug substances access to the CNS. The current clinical status of 4 is not known by the 
authors. 
 
2.1.5 Trichostatin A 
 Compound 5 is another HDAC inhibitor of the hydroxamic acid class.55 Compound 5, 
originally developed as an antifungal drug, is a member of a large class of HDAC inhibitors with 
a broad spectrum of epigenetic activities. A recent study showed that compound 5-treated 
SMAΔ7 mice continued to gain weight, maintained stable motor function, and retained intact 
neuromuscular junctions long after treatment was discontinued.55 Compound 5 treatment resulted 
in a 19% increase in median survival. When additional nutritional supplements were 
administered, median survival increased by 170%.55   
A 2014 study by Liu et al. found that 5 increased the median lifespan of SMN2B/- mice 
from 20 days to 8 weeks, significantly attenuated weight loss, and improved motor behavior.56 
Interestingly, 5 treatment did not increase the levels of SMN protein in mouse embryonic 
fibroblasts or myoblasts obtained from SMN2B/- mice. In addition, no change in the levels of 
SMN transcripts or protein in the brain or spinal cord of 5-treated SMA mice was observed. 
Furthermore, 5 did not increase SMN protein levels in the hind limb muscle, heart, or liver of 
SMN2B/- mice, suggesting that 5 acts independently of the SMA gene.  
 
2.1.6 Summary of HDAC Inhibitors 
 The hydroxamic acid class of HDAC inhibitors was the first to substantially improve the 
phenotype of SMA mice, with 5 and 4 increasing median survival by 40% and 30%, 
respectively.43,55 However, because 3 and 2 were already in clinical trials, these compounds were 
studied in SMA patients relatively quickly despite their low potency as HDAC inhibitors. Results 
from these studies have shown limited but positive effects in open-label studies in SMA Types II 
and III. The significantly more potent HDAC inhibitors 4 and 5 demonstrate poor HDAC 
selectivity and are considered to be too toxic for chronic use to potentially treat SMA. The zinc 
binding hydroxamic acid group is present in all of the HDAC inhibitors advanced into trials for 
SMA and is generally associated with poor pharmacokinetics and severe toxicity.  To fully 
evaluate the potential of HDAC inhibitors for the treatment of SMA, more potent, HDAC 
enzyme-specific, non-hydroxamic acid, CNS penetrant compounds are needed.  
2.2 NEUROPROTECTIVES 
2.2.1 Riluzole 
 Riluzole (6), a 2-aminobenzothiazole, is FDA-approved for the treatment of ALS.57 
Although 6 was proposed to modulate excitatory neurotransmission mainly through inhibition of 
glutamate release; the precise neuroprotective mechanisms remain largely speculative. Its 
pharmacologic properties that may be related to its effect include an inhibitory effect on 
glutamate release, inactivation of voltage-dependent sodium channels, and the ability to interfere 
with intracellular events that follow transmitter binding at excitatory amino acid receptors.   
Compound 6 exhibits neuroprotective effects in various in vivo experimental models of 
neuronal injury involving excitotoxic mechanisms. In in vitro models, 6 protected cultured rat 
motor neurons from the excitotoxic effects of glutamic acid and prevented the death of cortical 
neurons induced by anoxia.57,58 In ALS patients, 6 resulted in increased life expectancy and 
reduced rates of neurodegeneration. As a neuroprotective, it did not promote the recovery of lost 
motor neurons or show an improvement in muscle function. In SMA mouse models, 6 showed 
stabilization of neuromuscular junctions, but did not prevent the loss of proximal axons.  
Compound 6 is able to cross the BBB; however, it is a known substrate for the P-gp 
efflux transporter. An ALS mouse model showed how the upregulation of P-gp expression 
correlates with low levels of 6 in the brain. Although it is not known if P-gp is highly expressed 
in SMA, this concept may explain the inadequate levels of 6 found in in vivo studies. The poor 
pharmacokinetic properties of 6 also may contribute to its poor long-term efficacy.59,60  
A small Phase I clinical trial enrolling seven compound 6-treated and three placebo-
treated Type I SMA infants showed 6 to be safe. However, no significant differences in survival 
or motor abilities were observed.61 Nevertheless, further analysis showed that three patients in 
the 6 group presented an unusual disease course and were still alive at the age of 30 to 64 
months.62 It is unclear whether 6 is beneficial for SMA patients. 
2.2.2 Hydroxyurea 
Hydroxyurea (7), an FDA-approved compound for the treatment of solid tumors and 
sickle cell anemia, also has been considered for the treatment of SMA.63 Its ability to increase the 
expression of fetal hemoglobin suggested it might increase expression of SMN2. Compound 7 
treatment of SMA-derived lymphocytes stimulated increases in the levels of total and exon 7-
included SMN2 transcripts.63 A recent study suggested that 7 increases nitric oxide, which, in 
turn, increases SMN2 expression.64 Nevertheless, several clinical trials are underway to evaluate 
the therapeutic efficacy of 7. Early uncontrolled trials have shown positive trends, although none 
was statistically significant. A subsequent controlled trial reported no benefit of 7 in SMA 
treatment.65 
Compound 7 has poor brain penetration in rat (e.g., brain to plasma ratio of 0.12-0.25), 
although it is not considered to be a P-gp substrate.66 However, it has low lipophilicity (e.g., 
cLogP = -1.8 and hydrogen-bond donors (HBD) = 4). These physicochemical properties likely 
combine to limit passive transport across the BBB.  
2.3 ANTIBIOTICS 
2.3.1 Ceftriaxone 
Despite having physicochemical properties outside of those normally considered 
necessary for CNS penetration (e.g., MW = 554 amu, PSA = 208 Å2, hydrogen-bond acceptors 
(HBA) = 15), the β-lactam antibiotic ceftriaxone (8) crosses the BBB through active transport.67 
Though 8 was demonstrated to increase glutamate reuptake and improved the phenotype of ALS 
mice,68 a clinical trial of 8 in ALS was unsuccessful. Compound 8 was evaluated in severe SMA 
mice and showed a modest extended survival.69 Treated animals demonstrated a modestly 
improved neuromuscular phenotype and increased survival. The neuroprotective effect appears 
to be mediated by increased levels of the glutamate transporter Glt1, the transcription factor 
Nrf2, and SMN protein. This study provided the first evidence of a potential positive effect of β-
lactam antibiotics as a treatment for SMA, but further studies are needed.   
2.3.2 Albuterol 
 Another FDA-approved compound repurposed for SMA is albuterol (9).70 Compound 9 is 
a β2 adrenergic receptor agonist used to relieve the symptoms of asthma and chronic obstructive 
pulmonary disease and increase skeletal muscle strength.70 Compound 9 has been shown to 
increase full-length SMN transcript levels in severe SMA patient-derived cell lines. In SMA-
derived fibroblasts, 9 stimulated SMN2 mRNA and SMN protein production.71  
Compound 9 has poor brain penetration in rat (e.g., brain to plasma ratio of 1:20). The 
very low lipophilicity (e.g., cLogP <1) and the 4 H-bond donors likely hinder passive diffusion 
across the BBB.72 
A small, uncontrolled pilot study was performed to determine the clinical benefit of 9 in 
Type II and Type III SMA patients, and demonstrated a statistically significant increase in 
muscle function.73 An additional open-label trial using daily 9 treatments in Type II SMA 
patients reported possible functional improvement on the Hammersmith Motor Functional Scale. 
However, the data for this study should be cautiously interpreted because of the relatively small 
sample size and possible placebo effect.74 A sufficiently powered, randomized, double-blinded, 
placebo-controlled trial needs to be performed using 9 in SMA patients as none has been 
published to date.  
 
2.3.3 Aclarubicin 
 Aclarubicin (10) is a member of the anthracycline drug class approved for the treatment 
of acute non-lymphocytic leukemia that was identified in a cell-based screen for compounds that 
correct SMN2 splicing.75 Compound 10 was shown to increase both total and exon 7-included 
SMN2 transcripts as well as SMN protein in primary SMA-derived fibroblasts. Compound 10 
interacts with and antagonizes the activity of Type II DNA topoisomerases.5 Compound 10 can 
also intercalate into DNA and inhibit DNA replication, DNA repair, and RNA protein synthesis.  
 Despite observations of its activity on SMN expression by two independent groups,75,76 
the use of 10 is restricted due to intrinsic toxicity. However, other related anthracycline 
derivatives did not affect SMN2 splicing, suggesting that the mechanism underlying compound 
10-modulated splicing is different from other “anthracycline–like” activities. If the mechanism 
can be identified, it may be possible to design new analogs with less toxic effects.   
Name Structure Mode of Action MWa cLogPb PSAc HBAd HBDe Ref 
Sodium butyrate 
(1)  
Weak class 
I HDAC 
inhibitor 
110 0.6 26 2 1 39 
Sodium 
phenylbutyrate 
(2)  
Weak class 
I HDAC 
inhibitor 
186 2.0 26 2 1 40,45–49 
Valproic Acid 
(3) 
 Weak class 
I HDAC 
inhibitor 
144 2.8 37 2 1 41,50–54 
Suberoylanilide 
hydroxamic acid 
(4)  
Potent 
HDAC 
class I and 
II  
264 1.0 78 5 3 42,43
Trichostatin A 
(5)  
Potent 
HDAC 
class I and 
IIb 
302 1.9 70 5 2 44,55,56 
Riluzole (6) 
 
Neuro-
protective 234 3.2 48 4 2 
57–
62 
Hydroxyurea (7)  
Increases 
Nitric 
Oxide 
76 -1.8 75 4 4 63–66 
Ceftriaxone (8) 
 
Unknown 554 0.02 209 18 5 67–69 
Albuterol (9) 
 β2 Adrenergic 
Receptor 
Agonist 
239 0.06 73 4 4 70–74 
Aclarubicin (10) 
 
Antibiotic 812 3.4 217 16 4 75, 76 
aMW, molecular weight; bcLogP, calculated LogP; cPSA, polar surface area; dHBA, hydrogen-bond acceptor ; eHBD, 
hydrogen-bond donor. 
Table 1. Small molecules that were repurposed for the treatment of SMA. 
3. SMALL MOLECULES IN CLINICAL TRIALS 
3.1 NON-SPECIFIC TREATMENTS FOR SMA 
There are five small molecules currently being tested in Phase I to Phase III clinical trials for 
SMA. Two of these five compounds, neuroprotective olesoxime (11)77 and muscle protective 
CK-2127107 (structure not disclosed),78 are non-specific to SMA, meaning that the mechanism 
targets the CNS and muscles in general, and neither molecule directly affects the pathway of 
SMA. Each of these non-specific SMA small molecules will be discussed in terms of 
identification, rationale, mechanism of action, progression to date, and medicinal chemistry 
properties. 
3.1.1 Olesoxime 
Compound 11 is a novel neuroprotective compound that is non-specific to the disease 
mechanism of SMA (Table 2). This compound was identified in a cell-based screen as an agent 
protective against motor neuron death induced by neurotrophic factor withdrawal.79,80 This agent 
acts to preserve the integrity of mitochondria in neurons under cellular stress by preventing 
mitochondrial permeability transition pore openings. There is evidence that 11 binds to a 
translocator protein (18 kDa) and voltage-dependent anion channel, two proteins located on the 
outer mitochondrial membrane.80 Compound 11 is closely related to cholesterol and exists as a 
stable mixture of syn- and anti- isomers at the 3-position. Compound 11 is highly lipophilic 
(cLogP = 10) and is able to cross the BBB, although it has poor aqueous solubility at pH 7.4 and 
must be dosed orally in an oily excipient.77  
 Compound 11 was developed as a neuroprotective therapy for ALS and SMA. In vitro 
neuronal cell death studies demonstrated a dose-dependent increase in cell survival with the use 
of 11 in trophic factor deprivation assays. When dosed at 3 mg/kg in SOD1G93A transgenic 
mouse models of ALS, 11 resulted in the prevention of weight loss, a delay in severe muscle 
function decline, and a significant increase in lifespan. In another study, 11 was subcutaneously 
administered (30 mg/kg) daily to 21-day old SMNF7/F7 SMA mice and resulted in a significant 
increase in life span. Only 15% of vehicle-treated mice survived longer than 40 days, whereas 
45% of compound 11-treated mice lived beyond 40 days.77  
Compound 11 is brain penetrant and is not a P-gp substrate. In mice, daily doses of 11 (3 
mg/kg) resulted in a brain to plasma ratio of 0.35:1 after 7 days of treatment, and 0.51:1 after 42 
days of treatment. Indeed, in a mouse nerve crush study, repeated dosing demonstrated drug 
accumulation in brain tissue over time, while the drug concentrations in plasma remained 
constant.77  
Compound 11 did not provide significant treatment benefits during a Phase III clinical 
trial in patients with ALS, and it did not receive FDA approval. Although the compound showed 
no major effect on the survival of ALS patients, 11 was known to be safe in healthy individuals 
and was advanced directly into Phase II clinical trial studies for SMA.80,81 A randomized, 
double-blind Phase II clinical trial study was conducted to assess the efficacy and safety of 11 in 
SMA Type II and Type III non-ambulant patients ranging in age from 3 to 25 years old. 
Although no results were reported, a second Phase II clinical trial is underway. This trial, which 
is currently in the recruitment process, will focus on the nature, frequency, and severity of 
adverse events, as well as the effects on laboratory values, vital signs, and electrocardiography 
parameters. 
3.1.2 Compound CK-2127107 
 In collaboration with Astellas Pharma, Cytokinetics has developed CK-2127107, which is 
believed to be a 2-aminoalkyl-5-N-heteroarylpyrimidine derivative that slows calcium release 
from fast skeletal muscle troponin and sensitizes the sarcomere to calcium (Table 2). The 
sarcomere is the contractile unit of skeletal muscle in the body. Within the sarcomere, calcium 
ions (Ca2+) are the key regulatory ions in the signaling process. The binding of Ca2+ to troponin 
C in the troponin complex of the muscle allows tropomyosin movement, actin-myosin 
interaction, and muscle contraction.78 As the magnitude of Ca2+ release is proportional to the 
level of neuromuscular transmission and the force of muscle contraction, control of this ion 
provides a therapeutic target of interest to treat SMA and other skeletal muscle-related diseases.82 
With this mechanism of action, CK-2127107 helps increase skeletal muscle contractility and 
enhances physical performance in patients with neuromuscular diseases.78 
 Cytokinetics also developed an earlier small-molecule fast skeletal troponin activator, 
Tirasemtiv (12), and reported the first positive results from this mechanism of action by 
increasing skeletal muscle force and exercise performance in healthy and neuromuscular-
diseased rats.78 Compound 12 is structurally distinct from CK-2127107, but it demonstrates 
efficacy in improving muscle strength and produces a significantly higher force output at 
submaximal levels of motor nerve stimulation (Figure 2). Compound 12 is currently in Phase III 
clinical trials for ALS treatment and provides proof-of-concept for this mechanism of action. 
Through the same mechanism, CK-2127107 has displayed multiple areas of effectiveness, 
improving exercise tolerance in vivo in a rate model of heart failure-mediated skeletal myopathy, 
increasing sarcomere Ca2+ sensitivity in left anterior descending coronary artery heart failure 
(LAD-HF) skeletal fibers in vitro, increasing force output at submaximal stimulation frequencies 
in the diaphragm and hind-limb muscles, and improving performance in LAD-HF rats.78 
Importantly, CK-2127107 also has been shown to selectively activate fast skeletal myofibrils 
(EC50 = 3.4 umol/L and maximal activation = 3.6-fold increase) with no effect on slow skeletal 
or cardiac myofibrils. Although this study showed the effects of CK-2127107 in a heart failure 
rat model, there is a correlation between the effects in this mouse model and those of SMA 
mouse models, as both display significant muscle atrophy. CK-2127107 may decrease the 
severity of symptoms and allow for an increase in patient muscle function in SMA.78 The unique 
mechanism of CK-2127107 may allow combination therapy with agents that specifically 
increase levels of the SMN protein.  
A number of patents on the use of amino-pyridazines for the treatment of neuromuscular 
disorders (e.g., Markush 13, Figure 2) have published and the 2-aminopyridine (14) is shown as 
a representative analog.  
 
Figure 2. Examples of Cytokinetics small molecules.83,84 
Phase I clinical trials tested the safety, pharmacokinetics, and pharmacodynamics of CK-
2127107 in healthy individuals using three randomized, placebo-controlled studies. Single and 
repeated doses of the compound were well-tolerated and increased the response of muscle to 
nerve activation.85 With positive safety results in the first phase of clinical trials, the drug is now 
moving into Phase II studies. Cytokinetics has opened enrollment for this double-blind, 
randomized, placebo-controlled clinical trial to test the pharmacodynamics effect of CK-
2127107 on skeletal muscle function and fatigability in teens and adults with SMA Types II, III, 
and IV. 
3.2 SPECIFIC TREATMENT FOR SMA 
Treatment concepts shifted from non-specific to specifically targeting the SMN2 gene 
after this gene was discovered to produce normal SMN protein. The SMN2-derived SMN protein 
can be directly or indirectly upregulated through (i) increased transcription of SMN2, (ii) 
increased inclusion of exon 7 SMN2 (iii) stabilization of full-length exon 7-included SMN2 
mRNA, and (iv) stabilization of the SMN protein. In this section, the identification, rationale, 
mechanism of action, progression to date, and medicinal chemistry properties of each small 
molecule specific to SMA-targeted therapy in clinical trials will be discussed.  
3.2.1 Compound RG3039 (17) 
To identify compounds that increase the transcription of SMN2, a high-throughput, cell-
based screen was performed by Aurora Biosciences (which was subsequently acquired by Vertex 
Pharmaceuticals) under the sponsorship of Families of SMA.86 The screen identified a class of 
2,4-diaminoquinazolines (DAQ) (Figure 3; 15 and 16).86,87 The DAQ series of compounds was 
shown to increase total SMN2 mRNA with a proportional increase in exon 7-included SMN2 
mRNA transcripts and SMN protein in SMA patient-derived primary fibroblasts. Medicinal 
chemistry optimization of the DAQ series focused on modifications to the 5-position and 
ultimately led to the discovery of the O-linked 2,6-dichlorobenzyl piperidine analog 17 (Table 
2).88  
 
 
Figure 3. Discovery of clinical compound 17 and target ID probe compound 18.89 
 
Following a single oral dose (10 mg/kg) in adult mice, 17 resulted in low plasma 
exposure (e.g., AUClast (plasma) = 157 ng.h/mL), but it displayed significant partitioning into the 
brain (AUClast (brain) = 6762 ng.h/mL) and consequently resulted in a very high brain to plasma 
ratio of 16:1.  
Next, 17 was tested in three SMA mouse models. In the Taiwanese mouse model of 
SMA, in which the transgenic mice only have 2-4 copies of human SMN2 and no murine SMN 
(generated to be similar in survival to the SMAΔ7 by Li et al.), Compound 17-treated mice had 
improved motor abilities and a 38% increase in lifespan compared to vehicle-treated SMA 
mice.90 When tested in the intermediate 2B/– SMA mouse model (average survival 18.5 to 21 
days), 17 extended survival by 100% relative to vehicle. When the study ended on day 112, 27% 
of compound 17-treated mice were still alive. In addition to improved lifespan, the muscle 
function and weight gain of the compound 17-treated mice improved as well.88 
In order to identify the binding target of the DAQ series, a suitably active 125I 
radiolabeled compound was identified (Figure 3; 18) and used to identify potential binders in 
human protein microarrays.89 Compound 18 was found to bind the scaverger decapping enzyme 
(DcpS), and binding was confirmed using X-ray crystal structure determination.89,91-93 DcpS 
participates in 3’-5’ mRNA degradation, in which the protein targets the 5’ cap structure 
following 3’ end mRNA decay to release m7Gp and ppN products. In a separate pathway, DcpS 
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also was shown to be a cofactor for Xrn1, a 5’-3’ exoribonuclease, and to regulate RNA stability 
through a transcript-specific mode of action. Thus, small molecules in the quazoline series, such 
as 17, appear to stabilize RNA levels through inhibition of DcpS.94 
In the SMAΔ7 mouse model, 17 was administered intraperitoneally at 10 mg/kg for 10 
days and resulted in 90% DcpS inhibition within 2 h of the last dose. DcpS levels remained 80% 
inhibited 72 h after dosing. To examine the effects of 17 on survival in the SMAΔ7 mouse 
model, mice were treated with daily doses (10 mg/kg) until death. Drug-treated mice showed a 
26% increase in median survival in comparison to vehicle-treated mice and displayed an overall 
increase in weight gain and motor function. A modest increase in full-length SMN transcript 
levels was detected; however, no increase of the SMN protein in the CNS was detected.95,96 
Notably, 17 improved survival, muscle function, and weight gain in all three mouse models, 
which varied in SMA severity.   
A Phase I clinical trial to evaluate the safety profile of 17 in healthy volunteers began in 
2012. Repligen, Inc. has released several reports about the success of this trial, detailing the 
effectiveness of 17 and its minor side effects. Pfizer Inc. acquired rights to this compound but 
subsequently terminated the project and further development of 17 as a treatment for SMA is 
questionable. 
3.2.2 Compound RG7800 
PTC Therapeutics aimed to identify compounds that selectively modulate SMN2 
inclusion of exon 7. Through the use of a HEK293 human embryonic kidney cell line harboring 
an SMN2 mini-gene reporter assay, a library of proprietary small molecules was screened, and 
several chemical classes of compounds that induced exon 7 inclusion were identified. Deep 
sequencing of all mRNAs revealed that altered exon processing was highly specific to SMN2 
transcripts. Following medicinal chemistry optimization in a collaborative project with Roche, 
three orally available compounds (i.e., the coumarins SMN-C1 (19) and SMN-C2 (20) and the 
pyrido[1,2-a]pyrimidin-4-one SMN-C3 (21)) with nanomolar potency were identified.97 These 
compounds increased full-length SMN2 mRNA levels and concomitantly reduced Δ7 mRNA 
levels in SMA Type I patient fibroblasts after 24 h of treatment.97 
 
Figure 4. Examples of PTC/Roche small molecules. 
 
In RNA sequence studies, 21 was determined to be specific to SMA, displaying affinity 
for SMN2 exon 5 and 7 splice junctions. When dosed orally in the mild-type SMA mouse model, 
21 increased SMN2 mRNA and SMN protein in the brain and muscle tissues by 90% and 50-
70%, respectively. Compound 21 also showed an excellent PK profile; after oral administration 
(10 mg/kg), adult wild-type mice demonstrated a 3:1 brain penetration ratio and a plasma 
concentration peak of compound at approximately 2 to 2.5 h. In support of these findings, 
intraperitoneal injection of 21 in the severe SMNΔ7 mouse model resulted in increased SMN 
protein levels in the brain and muscle tissue by up to 150% and 90%, respectively. Dosing the 
animals daily with 21 (0.3 mg/kg) allowed 50% of the mice to survive past 40 days. Another 
study dosed Δ7 mice daily (1 or 3 mg/kg) and resulted in 90% survival until the end of the study 
or 65 days.97 
PTC Therapeutics, in partnership with Roche, advanced RG7800 (structure not disclosed) 
as its clinical candidate and began a Phase I single-ascending dose study.98 The study revealed 
that the compound was safe and well-tolerated in healthy volunteers. Following this success, 
adult and pediatric SMA patients began to enroll in a randomized, placebo-controlled Phase 
Ib/IIa clinical trial. However, PTC/Roche suspended this clinical trial over concerns regarding an 
eye condition that developed in long-term animal studies. A Phase I trial began recruiting healthy 
volunteers in January 2016 to evaluate the safety profile and pharmacokinetic tolerability of an 
alternative candidate, RG7916 (structure not disclosed). Dosing regimens in the study will 
include a combination of RG7916 and itraconazole, an antifungal, as well as a placebo.   
3.2.3 Compound LMI070 
Novartis performed a high-throughput screen of over 1.4 million compounds using a 
minor modification of the SMN2 splicing reporter construct described by Cherry et al.99 In this 
screening assay, the reporter was introduced into the NSC-34 mouse neuroblastoma/spinal cord 
hybrid cell line.100 With a hit rate of <1%, a pyridazine class of orally active small molecules was 
identified and shown to elevate levels of the full-length SMN protein via the inclusion of exon 7. 
After substantial lead optimization and drug discovery efforts, two compounds from this series, 
NVS-SM1 (22) and NVS-SM2 (23), showed increased exon 7 inclusion and upregulated SMN 
protein expression in both SMA patient fibroblasts and SMNΔ7 5025-mouse myoblasts (Figure 
5).100 The related analog NVS-SM3 (24) was inactive, indicating that the un-substituted pyrrole 
common to 22 and 23 is important for activity.100 
Short-term dosing of 22 (1 mg/kg and 3 mg/kg) in the severe SMNΔ7 mouse model 
demonstrated an increase in both SMN protein levels in the brain and survival of the animals by 
50% and 62% relative to the doses. In a long-term SMNΔ7 mouse model study, one cohort 
received daily doses of 22 (1 mg/kg) for an additional two weeks until day 49, and another 
received vehicle between days 36 and 49. Body weight and survival measurements between 
cohorts were nearly identical, supporting the duration effectiveness of 22 and suggesting that 
termination of treatment after 28 days allows sustained rescue from SMA phenotypic 
symptoms.100  
Unexpected effects of alternative splicing prompted RNA sequencing studies to 
determine if 22 changed global gene expression or splice site selection. Following 22 treatment, 
175 genes were altered by >2-fold with little difference in splicing factors or RNA binding 
proteins. Splice site analysis detected 39 22 specific events in 35 genes, indicating a very 
selective modulation of splicing. The mechanism of 22 exon 7 recognition was investigated with 
a series of chimeric splicing cassettes. This analysis revealed that the 21 nucleotides surrounding 
the 5’ splice site in intron 7 of SMN2 were enough to promote 22 specific changes in exon 7 
inclusion. Surface plasmon resonance established changes in the disassociation kinetics between 
the SMN2 mRNA and the U1 snRNP in the presence of 22, suggesting that it interacts with the 5’ 
splice site of SMN2 intron 7 and stabilizes its interaction with the U1 snRNP complex. 
Combined, these results provide the first mechanistic insights for a sequence-specific, small 
molecule splicing modulator.100 
The clinical lead compound in this series, LMI070 (structure not disclosed),101 has begun 
Phase II clinical trials to evaluate safety, tolerability, and efficacy in SMA patients. An open-
label, multi-part, first-in-human clinical trial is now recruiting in Europe. During the trial, 
LMI070 will be orally administered to Type I SMA infants to determine the maximum tolerated 
dose and optimal dosing regimen.  
 Figure 5. Examples of active and inactive pyridazines reported by Novartis. 
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Table 2. Chemical properties of small molecules in clinical development for SMA.  
 
4. PRECLINICAL SMALL MOLECULES 
There are six small molecules currently in preclinical development for the treatment of SMA. All 
of these compounds are reported to be specific to the SMA-disease pathway, although not all of 
the companies and academic laboratories have published data to support these claims. Without 
published data, many of these compounds cannot be assessed for medicinal chemistry properties 
and their progress remains unknown.  
4.1 Indiana University and the Laboratory for Drug Discovery in Neurodegeneration 
The Androphy group at Indiana University and the Laboratory for Drug Discovery in 
Neurodegeneration (LDDN) at Brigham and Women’s Hospital combined the SMN promoter 
with exons 1-6 and an exon 7 splicing cassette in a single construct with a luciferase reporter to 
identify compounds that increase SMN transcription, increase exon 7 inclusion, or potentially 
stabilize the SMN mRNA or protein. Stable clonal HEK293 cell lines that expressed SMN1 or 
SMN2 reporters were isolated to reduce variation due to factors such as plasmid number. Using 
this SMN2 reporter assay, over 115,000 compounds were screened at the LDDN, and two hit 
compounds (LDN-75654 (25) and LDN-76070 (28)) were discovered to increase SMN 
expression from the SMN2 gene (Table 3).99 
Compound 25 produced a >240% or 3.4-fold increase in the luciferase activity of the 
assay with an EC50 of 2 μM (Figure 6).  Compound 25 is a 5-isopropyl isoxazole bearing a 3-
chloro-4-fluorophenyl carboxamide at the 3-position. Compound 25 is compliant with Lipinski’s 
rules for drug-like molecules, has physicochemical properties that are considered suitable for 
BBB penetration102 (MW = 283 amu, cLogP = 3.4, PSA = 51 Å2, HBD = 1, HBA = 3), and 
promotes increases in SMN expression in SMA-derived fibroblasts. However, 25 was inactive 
for SMN protein induction in vivo. Administration to SMNΔ7 mice revealed that 25 did not 
consistently elevate levels of SMN protein in the brain or spinal tissue of the animals. Compound 
25 had poor aqueous solubility (6 M at pH 7.4) and a short microsomal half-life in mouse 
microsomes (T1/2 = 5 min). The lack of metabolic stability and poor solubility presumably 
accounts for its poor pharmacokinetics and disappointing performance in vivo. Modifications 
made to the aryl ring of 25 revealed that the 3-chloro-4-fluorophenyl could be replaced by a 
phenyl ring (Figure 6; LDN-5021 (26)) with a significant improvement in both potency (EC50 = 
0.28 μM) and solubility (59 M at pH 7.4), although the mouse microsomal stability was still 
poor (T1/2 = 5 min).103,104 The introduction of the 2-pyridyl group (Figure 6; LDN-5065 (27)) to 
replace the phenyl group gave a compound of similar potency and solubility to 26 but with 
significantly improved stability in mouse microsomes. 
 
Figure 6. Preliminary optimization of 25. 
 
The mechanism of action of 25 was studied in SMN2-luciferase reporter cell lines using 
qRT-PCR. No change was detected in the mRNA levels, but concentration-dependent increases 
were observed in luciferase activity, suggesting that 25 and its analogs function through a post-
transcriptional mechanism.99  
Another distinct hit, compound 28, produced a >180% or 2.8-fold increase in the 
luciferase activity of the assay, with an average EC50 of 8.3 μM (Figure 7).99 Compound 28 is a 
3,4-dihydroquinolinone and structurally distinct from the first lead, 25. Further, 28 follows 
Lipinski’s rules and had acceptable physicochemical properties for potential brain penetration 
(MW = 410 amu, cLogP = 3.3, PSA = 57 Å2, HBD = 1, HBA = 5). Using qRT-PCR, 28 was 
found to increase SMN transcription in the SMN2-luciferase reporter cell line.99  
 Additional in vitro studies showed 28 had good stability in mouse liver microsomes (T1/2 
= 40 min), but had poor aqueous solubility (4 M at pH 7.4). In a preliminary efficacy study, the 
un-optimized lead 28 was found to be active in vivo. Daily treatment of SMN∆7 mice with 28 
(20 mg/kg) increased SMN protein levels and survival. Compound 28-treated mice had a mean 
increase of SMN protein levels in the spinal cord up to 6-fold greater than untreated or vehicle-
treated animals. Additionally, median survival increased from 7 days (vehicle-treated) to 16 days 
(compound 28-treated), a 2.4-fold increase in lifespan.99  
 
4.2 NIH Chemical Genomics Center 
Using the cell-based SMN2-luciferase reporter assay previously described by Cherry et al., the 
NIH Chemical Genomics Center (NCGC) screened a library of 210,386 compounds to identify 
those that increased expression of full-length SMN transcripts.105 Following hit validation and 
prioritization, 1-(4-(4-bromophenyl) thiazol-2-yl)piperidine-4-carboxamide (29) was identified 
as a promising hit that increased SMN protein production in a dose-dependent manner (Figure 
7).105 
The hit, 29 (EC50 = 1.22 μM, 268% increase in SMN2) underwent medicinal chemistry 
optimization, including piperidine modification, thiazole replacement, and phenyl substitutions. 
Switching the location of the aryl substituent from the 4- to the 5-thiazole position and replacing 
the 4-bromo phenyl with the electron-donating 4-thiomethyl phenyl (e.g., ML200 (30), EC50 = 31 
nM, 576% increase in SMN2) conferred increased potency and efficacy (Figure 7).105 
Unfortunately, 30 had a very short half-life in mouse liver microsomes (T1/2 = 2 min) and low 
permeability in Caco-2 cells (Papp A to B = 1.6 x 10-6 cms-1 and Papp B to A = 0.2 x 10-6 cms-1) 
with a poor efflux ratio of 0.125.  
Replacement of a potential metabolic liability, the 4-thiomethyl phenyl group, by 3,4-
dihydro-2H-benzo[b][1,4]dioxepin-7-yl and replacement of the amide by carboxylic acid 
produced ML372 (31) (EC50 = 12 nM, 325% increase in SMN2).105 Compound 31 possessed a 
more stable half-life in mouse liver microsomes (T1/2 >60 min) and high permeability in Caco-2 
cells (Papp A to B = 33.8 x 10-6 cms-1 and Papp B to A = 44.1 x 10-6 cms-1) with an efflux ratio 
close to unity (i.e., 1.3).  
Pharmacokinetic studies in mice (oral dosing at 30 mg/kg) demonstrated that 31 reached 
high plasma levels (plasma Cmax = 44 M) with a long plasma half-life (T1/2 >11 h). However, 
there was significant resistance to brain penetration (brain Cmax = 1.2 M), and half-life in the 
brain was >13.7 h. In addition, 31 demonstrated high plasma protein binding (94.9%). Although 
31 showed good oral absorption, its poor CNS penetration and high plasma protein binding 
indicated that free levels of 31 in brain were likely to be low following higher oral dosing (30 
mg/kg).105  
To determine their mechanism of action, 30 and 31 were studied using qRT-PCR. RNA 
expression and exon 7 inclusion levels were measured within a SMA reporter cell line, in which 
there was no increase in exon 7 mRNA. These compounds may, therefore, act post-
transcriptionally to increase the stability of SMN protein by inhibition of its degradation.105  
 
Figure 7. Discovery of 30 and 31. 
 4.3 Kozikowski and Rubin Laboratories 
An image-based screen of annotated chemical libraries revealed that small molecule 
inhibitors of the glycogen synthase kinase (GSK-3) (e.g., alsterpaullone (32) and AR-A014418 
(33)) could elevate SMN levels (Figure 8).106 In general, GSK-3 is known to regulate protein 
stability. More specific to SMA, there is a consensus GSK-3 phosphorylation site on serine 4 of 
the SMN protein.106 When this residue becomes phosphorylated, SMN protein degrades at a 
faster rate. Compound 32 is a known GSK-3 inhibitor, and treatment of mouse motor neurons 
with 32 resulted in increased amounts of SMN protein levels.106,107 This evidence suggests that 
the inhibition of GSK-3 is a potential therapeutic approach to treat SMA.  
Kozikowski and Rubin recently described a potent ATP-competitive GSK-3 inhibitor, 
BIP-135 (34) (GSK-3 IC50 = 21 nm).108 In SMA patient fibroblasts, 34 (25 μM, 72 h exposure) 
stimulated a 7-fold increase in SMN protein levels and displayed neuroprotective properties in an 
SMA-related, cell-based model of oxidative stress-induced neurodegeneration. Subsequently, 34 
was administered daily by intraperitoneal injection to SMNΔ7 neonatal mice in multiple doses 
(25, 75, and 125 mg/kg) in 100% DMSO. Compound 34 did not increase motor function or 
levels of SMN mRNA or protein, but it did improve median survival in the SMNΔ7 mouse 
model at the 75 mg/kg dose, increasing the lifespan by 2 days in comparison to untreated 
mice.108   
Pharmacokinetic data (e.g., brain levels) were not reported for 34, and the choice of 
100% DMSO as the vehicle for the in vivo study suggests poor compound solubility.  
Nevertheless, the modest extension in survival demonstrates potential for GSK-3 inhibitors as 
therapeutics; however, more potent and selective inhibitors with better drug-like properties and 
pharmacokinetics are required.  
 
Figure 8. GSK-3 inhibitors: 32, 33, and 34. 
4.4 Paratek Pharmaceuticals 
As previously mentioned, 10 was identified in a cell-based screen specifically designed to 
detect SMN protein upregulation via increased inclusion of exon 7 in SMN2. Although the 
precise mechanism in which 10 increases SMN expression is unclear, it was demonstrated to 
change the splicing ratio between exon 7-included and exon 7-excluded SMN2 transcripts.75 
More importantly, 10 was found to be toxic in SMA Type I fibroblast 3061 cells dosed at 
concentrations >10 nM. Although toxic, the distinct mechanism of 10 was unlike any other 
tetracycline derivatives. Therefore, it is predicted that structure-activity relationship (SAR) 
studies can provide similarly structured compounds without the toxic effects.  
Paratek Pharmaceuticals reported that a lead compound from its novel series of 
tetracycline-like analogs, PTK-SMA1 (35) (Table 3), alters the splicing pattern of exon 7 and 
has shown progress in in vitro and in vivo studies.109 A dose of 35 (10 μM) increased the levels 
of SMN protein in SMA patient fibroblasts by about 40%, relative to vehicle-treated cells. 
Compound 35 (MW = 605 amu, cLogP = 1.3, PSA = 194 Å2) is a tetracycline derivative, 
modified at the C7 position of the tetracycline backbone.109 Due to its large molecular size and 
polarity, the compound does not demonstrate good CNS drug-like properties and is hindered in 
its ability to penetrate the brain tissue in vivo. When 35 was administered via intraperitoneal 
injection (25 and 50 mg/kg) in a mild SMA Type III mouse model over 6 days, a 1.5-fold 
increase of exon 7 inclusion within liver cells was found. Only data from liver was collected 
because the compound is unable to cross the BBB.109 Additional SAR studies must focus on 
BBB penetration to increase SMN expression in the CNS. Otherwise, the novel treatment may 
not be an effective therapy. No further information has been published on the progress of this 
preclinical phase project. 
4.5 BioBlast Pharma 
BBrm2 is the repurposed FDA-approved drug, azithromycin, redesigned in a proprietary 
intrathecal formulation. Azithromycin is an antibiotic approved to treat acute bacterial 
exacerbation of chronic obstructive pulmonary disease, acute bacterial sinusitis, and pneumonia, 
among other uses. Read-through agents cause skipping or read-through of the translational 
termination codon at the end of exon 7 and result in a protein that has an extended C-terminus.110 
Aminoglycoside antibiotics (from a class of FDA-approved drugs including tobramycin, 
geneticin, amikacin, and TC-007 (36)),111 were found to induce higher levels of functional SMN 
protein after administration at the stop codon of exon 7 in the SMN Δ7 protein; however, toxicity 
limited any attempts to translate these agents into therapeutic candidates. With a safe profile, 
BBrm2 was shown to increase SMN protein expression and function in SMA patient cell lines, 
as well as increase SMN expression of the spinal cord, body weight, motor function, and survival 
in a SMNRT transgenic mouse model dosed via intracerebroventricular (ICV) administration. 
BioBlast Pharma reported that testing of the small molecule has been extended to additional 
studies in the Burgheron mouse model, where significant increases in tail length, body weight, 
and tissue SMN levels were observed.112  
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Table 3. Preclinical small molecules in development for SMA.  
5. DISCUSSION 
Repurposed drugs offer significant savings in discovery and development time and costs. 
However, many repurposed drugs were not originally developed for diseases that required brain 
penetration, limiting their utility in CNS diseases. While many of the compounds described in 
the preceding section demonstrated promising in vitro activity (e.g., increased SMN protein 
levels or neuroprotection), often there was no evidence of adequate brain penetration or target 
engagement.102,113,114 Indeed, a number of the compounds studied in vitro and in vivo for SMA 
have very poor brain penetration. When repurposing an approved drug for a CNS disease, there 
is a risk that negative information about a particular target or disease mechanism may be 
generated in the rush to achieve Phase II efficacy studies. For example, although a potent, 
HDAC-enzyme-specific, brain-penetrant molecule may have utility in the treatment of SMA, the 
non-specific mechanism through which HDAC inhibitors such as 2 and 3 act means these drugs 
are likely to cause side effects with long term usage, decreasing interest for developing this class 
of compound. Furthermore, many of the clinical trials of repurposed drugs in SMA were open 
label and ineffectively powered in trial design, so that it is difficult to know whether the 
therapeutic strategy or target had validity. Nonetheless, much was learned on how to develop a 
clinical trial and evaluate outcome measures. For instance, transport of a severely ill SMA Type 
1 patient to a distant medical center could itself have deleterious effects that complicate trial 
result interpretations. There are also ethical issues in withholding or limiting palliative treatments 
during trials. Although repurposing small molecules can expedite clinical testing, opportunities 
were missed to develop new SAR and discovery molecules with suitable brain penetration, level 
of effect on the SMA target, off-target toxicity and specificity.   
Clinical trials with agents specifically designed to target SMA and SMN2 have been 
initiated. Evidence shows that increasing the amount of SMN protein has the potential to 
decrease disease severity and symptoms. Because the SMN2 gene was discovered to produce 
some SMN protein, it has become a specific therapeutic target for SMA even though the 
threshold level of SMN protein required to decrease SMA symptoms remains undetermined.115 
Depending on their mechanism of action, small molecules can be administered independently or 
in combination to help decrease SMA symptoms. Cherry et al. demonstrated the use and success 
of small molecule combination therapy targeted to SMA. The study used 25 (a small molecule 
that functions at the post-transcriptional level) and 28 (a small molecule that affects the 
transcription of the SMN2 gene) individually and in combination with the pan-HDAC inhibitor 4 
in the SMN2-luciferase reporter assay.99 The combination of 25 with either 28 or 4 produced a 
greater-than-additive stimulation of the SMN2-luciferase reporter. Not only does this 
complementation confirm the separate and distinct mechanisms in which the two compounds 
work, but the results also suggest a synergistic relationship. On the other hand, 4, when 
combined with 28, appeared to overwhelm the transcriptional machinery and obscure the effect 
of 28. These results suggest that the compounds stimulate SMN2-luciferase expression 
similarly.99 Therapeutic approaches that combine modalities acting though different pathways 
may maximally increase SMN protein production and be of greatest clinical benefit.  
Combination therapies can be applied to lead compounds when the mechanism of action 
is known and distinct for each molecule. Compound 11 and CK-2127107 might be paired with 
any SMA-specific treatment because the neuroprotective and muscular protective mechanisms 
provide them with a unique therapeutic opportunity compared to other treatments in the pipeline. 
Analyzing the mechanisms of more specific treatments, 17 has been shown to bind DcpS, an 
enzyme that participates in mRNA degradation.94 In comparison, LMI070 was determined to be 
a selective splicing module that works to increase the stabilization between U1 snRNP binding 
and the 5’ splice site.100 Compound 17 and LMI070 work to stabilize SMN2 mRNA levels and 
increase exon 7 inclusion of SMN2 mRNA, effectively working through two distinctive SMN2-
targeted pathways. Importantly, some evidence suggests that RG7800 works through a similar 
mechanism as LMI070. The exact mechanism of RG7800 has not been reported, but affinity 
studies demonstrated that the compound shows moderate specificity for SMN2 exon 5 and 7 
splice junctions.97 Based on their structural similarities, LMI070 and RG7800 may bind to the 
same protein or RNA structure in SMN2 intron 7. Expanding to other treatment types, the 
combination of IONIS-SMNRx, which increases exon 7 inclusion, with a drug that stabilizes the 
half-life of the SMN protein may be a more effective in clinical trials. With multiple therapeutic 
targets in the SMA disease pathway, there is the potential to manage the symptoms of SMA with 
a variety of treatment options and combinations.  
 
6. CONCLUSION 
Despite the lack of FDA-approved treatments for SMA, the last fifteen years have seen 
dramatic progress in the development of therapeutic strategies. These advances have widened 
our understanding of the disease process and helped researchers explore new options for 
treatment. Progress in the field of SMA therapy is attributed to understanding SMN function, 
SMN2 exon 7 splicing regulation, and the therapeutic opportunities that stem from SMN 
production defects. Thus far, the current use of repurposed drugs has not provided a short cut to 
disease treatment, due in large part to non-specific mechanistic pathways and lack of CNS-
penetration. However, neuroprotective compounds, such as 11, and muscle targeting agents, such 
as CK-2127107, continue to progress through clinical trials due to their ability to target general 
atrophy symptoms. Very novel approaches that appear to specifically enhance the inclusion of 
SMN2 exon represent strong evidence that drug-like molecules can target RNA splicing. The 
field of SMA continues to advance upon the construction of extensive biology findings, 
sophisticated drug screening technologies and medicinal chemistry efforts that have translated to 
numerous therapeutic opportunities for SMA.  
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